Insulet Corporation (PODD)

Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to CareJune 6, 2026 7:00 AM
Business Wire STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not only confirm the impact of Insulet’s technology today—it also fuels continued investment in breakthrough innovation designed to improve outcomes, reduce daily effort, and expand access to diabetes technology. Results from the STRIVE pivotal trial and the EVOLUTION 3 feasibility study, presented at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, demonstrate meaningful improvements in glucose control for people with diabetes using Insulet’s future AID system — Omnipod 6 — and unique fully closed-loop (FCL) system for type 2 diabetes.* “Omnipod 6 represents one of our biggest steps forward yet, with greater personalization and responsiveness to hyperglycemia, by delivering up to 50% more automated insulin, as shown in the STRIVE results,” said Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Chief Medical Officer at Insulet. “Our fully closed-loop system for type 2 diabetes is intentionally designed to unlock barriers to AID by managing mealtime insulin and simplifying workflows to expand clinic adoption. Strong results from EVOLUTION 3 bring us one big step closer to making fully closed-loop for type 2 diabetes a reality.” Together, results from STRIVE and EVOLUTION 3 underscore Insulet’s continued commitment to building a future where managing diabetes is dramatically simpler. This progress aligns with the Company’s innovation philosophy: build technology that doesn’t just do more but demands less. STRIVE Study Overview The STRIVE pivotal trial was designed to evaluate the safety and efficacy of the next-generation Omnipod 6 algorithm. The randomized, crossover study included 132 participants across the U.S., including 98 with type 1 diabetes and 34 with type 2 diabetes. The type 1 cohort spanned a broad age range, including 29 participants aged 2 to

Insulet to Participate in William Blair 46th Annual Growth Stock ConferenceMay 27, 2026 4:05 PM
Business Wire Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com. ©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260527354082/en/ Investor Relations: 
Clare Trachtman 
Vice President, Investor Relations 
ir@insulet.com  Media: 
Cristal Downing 
Senior Vice President, Chief Corporate Affairs Officer 
pr@insulet.com   Original: Insulet to Participate in William Blair 46th Annual Growth Stock Conference

Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International MarketsMay 26, 2026 4:05 PM
Business Wire Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery. This action is separate from the voluntary Medical Device Correction issued on March 12, 2026 affecting certain Omnipod 5 Pods in the U.S. and includes certain Pod lots distributed in the U.S. and affected international markets. Pods not included in the affected lots remain safe to use. Insulet identified that some Pods from specific lots may have a small tear in the tubing (cannula) just above the skin, between the Pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the Pod instead of being fully delivered into the body as intended, potentially leading to under-delivery of insulin. Individuals using an affected Pod may notice wetness on their skin or Pod adhesive or detect the smell of insulin. However, in some cases, this issue may be difficult to detect and go unnoticed. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), a serious medical condition that requires prompt medical treatment and can be life-threatening if not treated. Approximately 7 million Pods are included within the scope of this action, approximately 60% of which have been consumed or are expired. The Pods affected by this correction represent approximately 8.5% of 2025 global Omnipod Pod production. Globally, there have been 24 reports of serious adverse events associated with high blood glucose levels, including hospitalization and DKA. There have been no deaths reported. This issue does not affect continuous glucose monitoring (CGM) systems or CGM readings. The issue was identified through the Company’s ongoing product monitoring. Insulet has identified the cause of this manufacturing issue and implemented corrective actions designed to prevent recurrence. In addition, the Company has further strengthened its in-process monitoring and quality controls designed to detect cannula tears of this nature. Insulet is communicating proactively with affected customers and providing clear instructions to help them identify affected lots, discontinue use of impacted Pods, and obtain replacement Pods at no cost. The Company has sufficient supply available to replace affected Pods and does not anticipate any disruption to product availability. The U.S. Food and Drug Administration (FDA) and all other relevant regulatory authorities have been notified of this action. Important Information for Omnipod Pod Users
Customers should visit Check Pod Lot to confirm whether their Pod lot number is included in this voluntary Medical Device Correction and request replacement Pods at no cost. A full list of affected lots is available on this site. If a Pod from an affected lot is currently in use, customers should discontinue use and replace it with a Pod from an unaffected lot. Customers in the U.S. who have questions or need assistance may contact Insulet Product Support at 1-800-641-2049 (available 24/7) or use the live agent chat at www.omnipod.com/current-podders. Customers outside the U.S. should visit www.omnipod.com and click the banner at the top of the page for more information. Forward-Looking Statement:
This press release includes certain forward-looking statements within the meaning of the Private Litigation Securities Reform Act of 1995, as amended. Forward-looking statements relate to future events, including statements concerning the Company’s plans or expectations regarding any voluntary medical device correction and effects of any voluntary medical device correction on the Company’s business, operations, and financial performance or guidance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control, that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, plans, guidance, estimates and projections, including (but not limited to) the financial, operational, and reputational impact and costs of any voluntary medical device correction, future actions by the FDA and other regulatory bodies, the possibility that any voluntary medical device correction could subject the Company to disputes, claims or proceedings that may adversely affect its business and financial operation and other factors detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2025. The Company encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances except as required by applicable law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260526676657/en/ Media Contact:
Cristal Downing
Chief Corporate Affairs Officer
pr@insulet.com Investor Relations:
Clare Trachtman
Vice President, Investor Relations
ir@insulet.com Original: Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets

Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.March 12, 2026 4:05 PM
Business Wire

Medical Device Correction impacts only specific lots of Omnipod® 5 Pods



Customers can visit omnipod.com/check-pods to check lot numbers and request replacement Pods at no cost



All other Omnipod® 5 Pods and Omnipod® products remain safe to use



Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”) today initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring. This action applies to specific identified lots distributed in the United States, and all other Omnipod® 5 Pods and Omnipod® products remain safe to use.


Insulet identified that certain Pods from specific lots may have a small tear in the internal tubing that delivers insulin. If this occurs, insulin may leak inside the Pod instead of being fully infused into the body as intended.


If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), a serious medical condition that requires prompt medical treatment.


Insulet has received 18 reports of serious adverse events associated with high blood glucose levels, including hospitalization and DKA. No deaths have been reported.


This issue does not affect continuous glucose monitoring (CGM) systems or CGM readings.


Following its investigation, Insulet has implemented updates to its manufacturing processes and quality controls to strengthen detection and prevention and further support the integrity of its products. The Pods involved in this correction represent approximately 1.5% of annual Omnipod® 5 pod production globally.


Insulet continues to manufacture and ship Omnipod® 5 Pods and does not anticipate disruption to customer shipments, product availability, or new patient starts.


The U.S. Food and Drug Administration (FDA) has been notified of this action. Patient safety and product quality remain Insulet’s highest priorities.


Important Information for Omnipod® 5 Users


Customers should visit omnipod.com/check-pods to confirm whether their Pod lot number is included in this voluntary Medical Device Correction and request replacement Pods at no cost.


If a Pod from an affected lot is currently in use, customers should discontinue use and replace it with a Pod from an unaffected lot.


Customers who have questions or need assistance may contact Insulet Product Support at 1-800-641-2049 (available 24/7) or use the live agent chat at omnipod.com/current-podders.


About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod® 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod® 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.


Forward-Looking Statement:

This press release includes certain forward-looking statements within the meaning of the Private Litigation Securities Reform Act of 1995, as amended. Forward-looking statements relate to future events, including statements concerning the Company’s plans or expectations regarding the voluntary medical device correction and effects of the voluntary medical device correction on the Company’s business, operations, and financial performance or guidance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control, that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, plans, guidance, estimates and projections, including (but not limited to) the financial, operational, and reputational impact and costs of the voluntary medical device correction, future actions by the FDA and other regulatory bodies, the possibility that the voluntary medical device correction could subject the Company to disputes, claims or proceedings that may adversely affect its business and financial operation and other factors detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2025. The Company encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260312976912/en/
Media:

Cristal Downing

Chief Corporate Affairs Officer

pr@insulet.com


Investor Relations:

Clare Trachtman

Vice President, Investor Relations

ir@insulet.com


Original: Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.

Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 DiabetesMarch 11, 2026 4:01 PM
Business Wire

Outcomes from EVOLUTION 2 study include 68% time in range with no boluses



Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve outcomes, and redefine user and clinician experience



Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has shared new clinical evidence related to the development of its first fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes.


“Developing and bringing to market a fully closed-loop AID system for people with type 2 diabetes—one that delivers therapy effortlessly and adapts automatically with no mealtime interactions or adjustments—is more than evolutionary; it’s revolutionary,” said Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Chief Medical Officer. “Our latest EVOLUTION study brings us another important step closer to addressing significant unmet needsB while redefining both the provider and user experience.”


Presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona, Spain, EVOLUTION 2C is the second in a series of feasibility studies supporting the development of an Omnipod fully closed-loop system.


This multicenter feasibility study was designed to drive rapid innovation, allowing investigators to evaluate multiple versions of the algorithm to support continued FCL system development. It included 24 adults in a highly diverse cohort from New Zealand, aged 16-70 years with type 2 diabetes using insulin (basal-bolus or basal-only, pumps or injections with HbA1c under 12.0%). The participants had lived with type 2 diabetes for an average of 16 years.


When using the final algorithm version of FCL with no boluses, the participants’ time in range (TIR) increased to an average of 68%, a 24% improvement over standard injection therapy. Time Below Range (TBR) remained very low, with a median of 0.14% below 70 mg/dL—well under the American Diabetes Association’s recommended threshold of less than 4%. No severe hypoglycemia or diabetic ketoacidosis (DKA) events were observed. Users experienced improved glycemic outcomes without compromising on low glucose events. The benefits were observed across a diverse set of participant characteristics including sex, ethnicity, baseline HbA1c, and body mass index. More than 90% of participants chose to continue into the ongoing extension phase, showing strong interest and positive experiences with the FCL system.


“The EVOLUTION 2 study results show a high time in range can be reached using an easy to use, intuitive system that is fully automated with no mealtime interactions. This adds to the growing evidence in support of automated insulin delivery and how innovations grounded in science can improve outcomes, reduce stress, and make diabetes a smaller part of everyday life,” said Dr. Martin de Bock, Professor and Pediatric Endocrinologist at the University of Otago, Christchurch in New Zealand. Dr. de Bock served as Chief Investigator for the EVOLUTION 2 study.


Evolving toward a breakthrough


EVOLUTION 2 builds on the 2024 EVOLUTION 1D feasibility study, which was the first evaluation of the Omnipod FCL algorithm in adults with type 2 diabetes. Participants in the EVOLUTION 1 study experienced significant improvements in TIR, from 52% to 65%, without boluses, representing more than three additional hours per day in target range with minimal hypoglycemia.


Insulet used these results to fine-tune the algorithm design, focusing on further simplifying the user experience and laying the groundwork for additional improvements studied with EVOLUTION 2.


The Company plans to start its pivotal study (EVOLVE) in 2026 to support a 510(k) filing in 2027 and a commercial launch in 2028.




A The FCL AID System is an investigational device. Limited by Federal (or United States) law to investigational use. This product has not been reviewed by the FDA or other regulatory agency.








B Only a quarter of individuals with type 2 diabetes on insulin are achieving an HbA1c of 7.0% or less, and half of this population has an HbA1c greater than 8.0%, Venkatraman S, et al. Trends and Disparities in Glycemic Control and Severe Hyperglycemia Among U.S. Adults with Diabetes Using Insulin, 1988-2020. JAMA Netw Open. 2022 Dec 1;5(12).








C https://clinicaltrials.gov/study/NCT07039981








D https://journals.sagepub.com/doi/full/10.1089/dia.2024.0463







About Insulet Corporation:


Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information visit: insulet.com and omnipod.com.


©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.


Forward-Looking Statement:


This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 21, 2025 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary materially from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311660681/en/
Investor Relations: 

Clare Trachtman 

Vice President, Investor Relations 

ir@insulet.com 


Media: 

Angela Geryak Wiczek 

Senior Director, Corporate Communications 

pr@insulet.com


Original: Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes

Accessible Health Platforms Gain Scale Across $6T Health and Wellness MarketFebruary 13, 2026 11:26 AM
PR Newswire (US)

ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.VANCOUVER, BC, Feb. 13, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual consumer spending, underpinned by rising demand for functional products that deliver measurable outcomes beyond basic nutrition[1]. At the same time, the FDA's updated "Healthy" labeling framework and stricter clean-label regulations are reshaping how brands formulate and position consumer health products, pushing innovation toward sugar-free, preservative-free, and portable delivery systems[2]. Five companies operating along that accessibility curve include Doseology Sciences (CSE: MOOD), Amneal Pharmaceuticals (NASDAQ: AMRX), Prestige Consumer Healthcare (NYSE: PBH), Viking Therapeutics (NASDAQ: VKTX), and Insulet (NASDAQ: PODD).A recent Global Wellness Summit forecast identifies personalized oral delivery and functional reformulation as defining themes for 2026, as consumers prioritize convenience, clinical credibility, and precise dosing[3]. That convergence of wellness innovation and broader healthcare accessibility is channeling capital toward platforms built around scalable, consumer-centric health delivery[4].Doseology Sciences Inc. (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70) recently launched pilot production of caffeine-based energy pouches in January 2026, marking the Feed That Brain brand's entry into the fast-expanding oral pouch category. Based in Kelowna, British Columbia, Doseology Sciences is producing nicotine-free pouches that deliver measured caffeine doses in a compact, portable format, drawing on the same consumer shift that turned tobacco-free nicotine pouches into a multibillion-dollar segment.The pilot pouches skip the sugar, carbonation, and liquid volume found in conventional energy drinks. A direct-to-consumer test phase is planned to collect customer feedback and operational data ahead of any broader commercial launch."This pilot reflects a disciplined and intentional approach to evaluating new product formats within our platform," said Tim Corkum, President and COO of Doseology Sciences. "Feed That Brain brings a strong foundation in functional product design, and this initiative allows us to assess caffeine-based, pouch-format energy delivery under a measured and compliant framework."The energy pouch program grew out of Doseology Sciences' August 2025 acquisition of the Feed That Brain brand for $400,000, paid entirely through stock issuance. Feed That Brain, a Toronto-based cognitive health label founded by Forbes-recognized entrepreneur Rena R. Dempsey, built its reputation on functional gummies and nootropic supplements designed to support mental performance.Doseology Sciences also secured Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units. Mimran co-founded Alfred Sung, founded Club Monaco (later acquired by Ralph Lauren), and created the Joe Fresh retail brand. He cited the company's product development process and attention to regulatory compliance as reasons for joining.Two large market tailwinds support the strategy. Grand View Research projects the global energy drinks market will grow from $79.4 billion in 2024 to $125.1 billion by 2030. The nicotine pouch segment is forecast to climb from $5.4 billion in 2024 to over $25 billion by 2030, reflecting a 29.6% annual growth rate. Rising consumer concern over sugar intake and beverage overconsumption continues to push demand toward alternative caffeine delivery methods.Doseology Sciences currently distributes Gummies and Collagen products under the Feed That Brain brand across close to 500 Canadian retail locations. Its U.S. subsidiary, Doseology USA Inc., established earlier this year, is working on pouches that blend caffeine with nootropics and adaptogens. The leadership team now includes CEO Chris Jackson, President and COO Tim Corkum, and Strategic Go-to-Market Advisor Patrick Sills.CONTINUED... Read this and more news for Doseology Sciences at:https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/Amneal Pharmaceuticals (NASDAQ: AMRX) introduced a new brand identity reflecting its evolution into a diversified global biopharmaceutical leader, anchored by a refreshed logo symbolizing the trust placed in healthcare providers and the real-world impact of each prescription. The company now delivers more than 160 million prescriptions annually across a portfolio of over 290 medicines."As Amneal has grown and diversified, our brand needed to evolve with us," said Chirag Patel, Co-Founder and Co-CEO of Amneal Pharmaceuticals. "This new brand reflects who we are today and where we are headed. It signals our ambition, our capabilities, and our unwavering focus on expanding access to medicines that make a meaningful difference in people's lives."Amneal Pharmaceuticals plans to introduce its Accessibility Index later this year, a platform designed to demonstrate real impact on affordability, availability, and innovation across its portfolio spanning complex generics, injectables, biosimilars, and specialty therapies.TheraTears, a subsidiary of Prestige Consumer Healthcare (NYSE: PBH), expanded its dry eye portfolio with two new products launching nationwide in February 2026: Eyelid Cleansing Wipes and Dry & Tired Preservative Free Lubricant Eye Drops. The preservative-free drops contain twice the hydrating ingredient of TheraTears' original formula and target consumers experiencing screen-related eye fatigue.The Eyelid Cleansing Wipes are formulated for gentle daily use with a non-stinging formula that removes irritants aggravating dry eye symptoms. Both products will be available at Amazon, Walgreens, and Walmart as part of the ophthalmologist-created brand's growing family of eye care solutions under Prestige Consumer Healthcare.Viking Therapeutics (NASDAQ: VKTX) reported fourth quarter and full-year 2025 financial results highlighting rapid progress across its obesity portfolio, ending the year with $706 million in cash to fund near-term catalysts including Phase 3 VANQUISH trials for subcutaneous VK2735. VANQUISH-1 enrollment exceeded 4,500 patients ahead of schedule, while VANQUISH-2 nears full enrollment."The past year was an exceptional year for Viking marked by rapid progress across our obesity portfolio," said Brian Lian, Ph.D., CEO of Viking Therapeutics. "We also expect to file an IND for our novel amylin agonist this quarter, expanding our obesity franchise."Viking Therapeutics plans to advance oral VK2735 into Phase 3 development in the third quarter of 2026, with maintenance dosing study results also expected in that period. The dual GLP-1/GIP agonist demonstrated up to 14.7% weight loss from baseline in its Phase 2 VENTURE trial.Insulet (NASDAQ: PODD) launched its Omnipod 5 Automated Insulin Delivery System across Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, bringing the tubeless wearable pump's global availability to 19 countries. The company simultaneously debuted Omnipod Discover, a proprietary data analytics platform designed to simplify glucose and insulin delivery insights for users and healthcare providers."We're proud to bring Omnipod 5 to a region where the unmet need is great," said Pat Crannell, Senior Vice President and International General Manager of Insulet. "It is even more meaningful and impactful with the inaugural introduction of Omnipod Discover, which simplifies data management and helps us create a world where diabetes demands less, every day."Insulet plans to launch Omnipod 5 in Spain later in 2026, followed by Greece and Croatia in the first half of 2027. Omnipod Discover will roll out to additional international markets after the Middle East introduction.Article Source: https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/ CONTACT:Equity Insider
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). "). This article is being distributed for Maynard Communications ("MAY"), who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Doseology Sciences. Inc. advertising or digital media, but expects to be paid a fee from ("MAY"). There may be 3rd parties who may have shares of Doseology Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Doseology Sciences Inc., which were purchased as a part of a private placement. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Doseology Sciences Inc.; this is a paid advertisement, we currently own shares of Doseology Sciences Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:1.   https://www.precedenceresearch.com/functional-beverages-market2.   https://www.mordorintelligence.com/industry-reports/global-functional-food-market3.   https://globalwellnessinstitute.org/press-room/press-releases/global-wellness-summit-releases-10-wellness-trends-for-2026/4.   https://insights.citeline.com/hbw-insight/perspectives/consumer-health-and-wellness-market-outlook-what-trends-will-impact-self-care-in-2026-T7WQJYMDZJE4FLRJAEHVIT7REE/Logo - https://mma.prnewswire.com/media/2840019/5798142/Equity_Insider_Logo.jpg 





View original content to download multimedia:https://www.prnewswire.com/news-releases/accessible-health-platforms-gain-scale-across-6t-health-and-wellness-market-302687851.html

Original: Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market

PODD WEEKLY

PODD 10 MINUTES

I would steer clear considering the FDA has updated their recall of Insulet's Omnipod (which I believe is their main if not their only product). It is now a class 1 recall, the most serious type they issue.

FDA Link: http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm461870.htm

EPE= - .93

PICTURE OF PUMP

Inst % Owned = 96%

PODD D 4 MONTHS

Insulet's OmniPod--Courtesy of Insulet

Insulet ($PODD) said its long-troubled Billerica, MA manufacturing plant is back on track on an earnings call earlier this month--just before the FDA offered details on the OmniPod recalls that were caused by inadequate standards compliance. In July, the company issued a voluntary recall of more than 400,000 OmniPod Insulin Management Systems, which are wearable insulin pumps.

The recall involved 12 product lots in the U.S. and 7 in Europe that were distributed from December 2013 through March 2015. In March, FDA conducted an inspection of the Billerica facilities for which Insulet received a warning letter from the agency.

On a mid-August earnings call, the company said the FDA had reviewed its corrective action and response and identified them as adequate. Insulet has implemented higher standards in its quality control procedures and it doesn't think much of the affected product remains with customers.

"While the product in these lots were manufactured in compliance with our standard operating procedures and met the final acceptance criteria in place at the time, we have since implemented procedures that have set the product quality bar even higher," Insulet President and CEO Patrick Sullivan said on the call.

"We initiated this product replacement proactively and we believe the vast majority of the product is no longer in the field," he added. Sullivan said that he didn't expect to see any adverse impact to the company's ongoing business and operations. In July, to help prevent future quality control issues, Insulet added Michael Spears as VP of Quality, Regulatory and Clinical Affairs. He previously held a similar position at Covidien.

The FDA said the affected OmniPod lots resulted in 90 reports of problems, of which 13 required medical intervention. But no serious injuries or deaths have been reported related to the recalled products.

This recall plagued the launch of the most recent version of the OmniPod. In the next few months, Insulet expects to submit to the FDA for an approval of its next-generation Personal Diabetes Manager (PDM), which controls the OmniPod. It anticipates a 2016 launch for the next-gen PDM.

Insulet is down by 37% in 2015 so far with a share price that has dipped to just below $30 and a market cap of almost $1.7 billion.

At least one analyst is optimistic about the prospects for the wearable insulin pump OmniPod. On the August earnings call, Leerink analyst Danielle Antalffy raised her price target to $44 from $40 a share.

She expects $309 million in 2015 sales, with $393 million in 2016. She expects that Insulet won't reach profitability until 2017, as it ramps up its R&D spending and sales force expansion. On the recent earnings call, Insulet reaffirmed its 2015 revenue guidance of $305 million to $320 million.

$PODD recent news/filings

bullish

## source: finance.yahoo.com

Fri, 26 Jun 2015 20:51:56 GMT ~ SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Insulet Corporation of Class Action Lawsuit and Upcoming Deadline - PODD

[Marketwired] - Pomerantz LLP announces that a class action lawsuit has been filed against Insulet Corporation and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, ...

read full: http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-205156627.html
*********************************************************

Fri, 26 Jun 2015 19:51:00 GMT ~ IMPORTANT INVESTOR ALERT: Goldberg Law PC Reminds Investors With Losses Greater Than $100,000 In Insulet Corporation Of July 6, 2015 Deadline

[Business Wire] - Goldberg Law PC reminds investors in Insulet Corporation , who purchased or otherwise acquired shares between February 27, 2013 and April 30, 2015, inclusive , of the July 6, 2015 deadline to file a motion to be appointed as lead plaintiff.

read full: http://finance.yahoo.com/news/important-investor-alert-goldberg-law-195100944.html
*********************************************************

Thu, 25 Jun 2015 18:23:07 GMT ~ SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Insulet Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2015 -- PODD

[GlobeNewswire] - NEW YORK -- The following statement is being issued by Levi & Korsinsky, LLP:

read full: http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-182307476.html
*********************************************************

Tue, 23 Jun 2015 14:29:57 GMT ~ ALERT: Morgan & Morgan Announces That Class Action Lawsuits Have Been Filed Against Insulet Corporation -- PODD

[GlobeNewswire] - NEW YORK -- Morgan & Morgan announces that class action lawsuits have been filed in the United States District Court for the District of Massachusetts, against Insulet Corporation ("Insulet" ...

read full: http://finance.yahoo.com/news/alert-morgan-morgan-announces-class-142957733.html
*********************************************************

Mon, 22 Jun 2015 19:19:03 GMT ~ SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Insulet Corporation and a Lead Plaintiff Deadline of July 6, 2015 -- PODD

[GlobeNewswire] - NEW YORK -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Insulet Corporation ...

read full: http://finance.yahoo.com/news/shareholder-alert-law-offices-vincent-191903300.html
*********************************************************

$PODD charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$PODD company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/PODD/company-info
Ticker: $PODD
OTC Market Place: Not Available
CIK code: 0001145197
Company name: Insulet Corp.
Incorporated In: DE, USA

Business Description:

$PODD share structure

## source: otcmarkets.com

Market Value: $1,807,517,152 a/o Jun 26, 2015
Shares Outstanding: 56,750,931 a/o Apr 28, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$PODD extra dd links

Company name: Insulet Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PODD/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PODD/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PODD+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PODD+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PODD+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/news - http://finance.yahoo.com/q/h?s=PODD+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PODD/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PODD/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PODD/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PODD/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PODD+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PODD
DTCC (dtcc.com): http://search2.dtcc.com/?q=Insulet+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Insulet+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Insulet+Corp.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PODD/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PODD
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PODD/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PODD/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PODD/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001145197&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PODD/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PODD/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PODD&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PODD
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PODD+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PODD+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PODD
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PODD
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PODD+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PODD/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PODD+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PODD.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PODD
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PODD/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PODD/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PODD/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PODD
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PODD
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PODD:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PODD
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PODD



$PODD DD Notes ~ http://www.ddnotesmaker.com/PODD

$PODD recent news/filings

turned bearish

## source: finance.yahoo.com

Tue, 07 Apr 2015 20:08:57 GMT ~ Insulet Corporation to Announce First Quarter 2015 Financial Results on April 30, 2015

[at noodls] - BILLERICA, MA -- (Marketwired) -- 04/07/15 -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced plans to release ...

read full: http://www.noodls.com/view/D5F80BA314A72A5C5849A32FB99179DE6C5C53CB
*********************************************************

Tue, 07 Apr 2015 20:01:00 GMT ~ Insulet Corporation to Announce First Quarter 2015 Financial Results on April 30, 2015

[Marketwired] - Insulet Corporation , the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced plans to release its financial results for the first quarter of 2015 on ...

read full: http://finance.yahoo.com/news/insulet-corporation-announce-first-quarter-200100316.html
*********************************************************

Wed, 01 Apr 2015 20:34:41 GMT ~ INSULET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement


read full: http://biz.yahoo.com/e/150401/podd8-k.html
*********************************************************

Tue, 31 Mar 2015 19:18:15 GMT ~ CFO Moves: Enterprise Products Partners, Insulet, Iconix Brand Group


read full: http://blogs.wsj.com/cfo/2015/03/31/cfo-moves-enterprise-products-partners-insulet-iconix-brand-group/?mod=yahoo_hs
*********************************************************

Tue, 31 Mar 2015 13:08:48 GMT ~ Wedbush Securities Sees Insulet Strengthen Bench By Hiring Experienced CFO


read full: http://finance.yahoo.com/news/wedbush-securities-sees-insulet-strengthen-130848115.html
*********************************************************

$PODD charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$PODD company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/PODD/company-info
Ticker: $PODD
OTC Market Place: Not Available
CIK code: 0001145197
Company name: Insulet Corp.
Incorporated In: DE, USA

Business Description:

$PODD share structure

## source: otcmarkets.com

Market Value: $1,679,326,840 a/o Apr 17, 2015
Shares Outstanding: 56,447,961 a/o Feb 20, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$PODD extra dd links

Company name: Insulet Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PODD/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PODD/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PODD+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PODD+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PODD+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/news - http://finance.yahoo.com/q/h?s=PODD+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PODD/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PODD/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PODD/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PODD/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PODD+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PODD
DTCC (dtcc.com): http://search2.dtcc.com/?q=Insulet+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Insulet+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Insulet+Corp.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PODD/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PODD
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PODD/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PODD/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PODD/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001145197&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PODD/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PODD/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PODD&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PODD
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PODD+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PODD+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PODD
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PODD
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PODD+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PODD/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PODD+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PODD.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PODD
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PODD/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PODD/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PODD/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PODD
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PODD
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PODD:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PODD
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PODD



$PODD DD Notes ~ http://www.ddnotesmaker.com/PODD

$PODD recent news/filings

bullish
double bottom pattern almost complete

## source: finance.yahoo.com

Thu, 07 Aug 2014 20:38:57 GMT ~ INSULET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/140807/podd8-k.html
*********************************************************

Thu, 07 Aug 2014 20:05:00 GMT ~ Insulet Reports Second Quarter 2014 Results

[Marketwired] - Insulet Corporation , the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced financial results for the three and six months ended June 30, 2014.

read full: http://finance.yahoo.com/news/insulet-reports-second-quarter-2014-200500009.html
*********************************************************

Thu, 07 Aug 2014 11:07:06 GMT ~ Q2 2014 Insulet Corporation Earnings Release - After Market Close


read full: http://biz.yahoo.com/research/earncal/20140807.html?t=podd
*********************************************************

Tue, 05 Aug 2014 21:49:36 GMT ~ Insulet and Dexcom Agree to Develop a CGM-Integrated Personal Diabetes Manager

[at noodls] - BEDFORD, MA -- (Marketwired) -- 08/05/14 -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, and DexCom, Inc (NASDAQ: DXCM), ...

read full: http://www.noodls.com/view/1A2A6A4C1703C0E913A0410CC27FE5A497C26BD9
*********************************************************

Tue, 05 Aug 2014 20:05:00 GMT ~ Insulet and Dexcom Agree to Develop a CGM-Integrated Personal Diabetes Manager

[Marketwired] - Insulet Corporation , the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, and DexCom, Inc , the leader in continuous glucose monitoring technology, today announced ...

read full: http://finance.yahoo.com/news/insulet-dexcom-agree-develop-cgm-200500209.html
*********************************************************


$PODD charts

basic chart ## source: stockcharts.com



basic chart ## source: eoddata.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$PODD company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/PODD/company-info
Ticker: $PODD
OTC Market Place: Not Available
CIK code: 0001145197
Company name: Insulet Corp.
Incorporated In: DE, USA

Business Description:


$PODD share structure

## source: otcmarkets.com

Market Value: $1,918,729,002 a/o Aug 08, 2014
Shares Outstanding: 55,414,556 a/o May 02, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$PODD extra dd links

Company name: Insulet Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PODD/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PODD/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PODD+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PODD+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PODD+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/news - http://finance.yahoo.com/q/h?s=PODD+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PODD/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PODD/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PODD/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PODD/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PODD/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PODD+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PODD
DTCC (dtcc.com): http://search2.dtcc.com/?q=Insulet+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Insulet+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Insulet+Corp.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PODD/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PODD
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PODD/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PODD/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PODD/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001145197&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PODD/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PODD/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PODD&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PODD
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PODD+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PODD+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PODD
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PODD
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PODD+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PODD/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PODD+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PODD.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PODD
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PODD/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PODD/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PODD/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PODD/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PODD
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PODD
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PODD:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PODD
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PODD



$PODD DD Notes ~ http://www.ddnotesmaker.com/PODD

~ Monday! $PODD ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $PODD ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=PODD&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=PODD&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=PODD
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=PODD#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=PODD+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=PODD
Finviz: http://finviz.com/quote.ashx?t=PODD
~ BusyStock: http://busystock.com/i.php?s=PODD&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=PODD >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Insulet Corporation is a medical device company that develops, manufactures and markets an insulin infusion system for people with insulin-dependent diabetes. The Company’s OmniPod Insulin Management System (OmniPod System), which consists of its OmniPod disposable insulin infusion device and its handheld, wireless Personal Diabetes Manager, is an insulin infusion system of its kind. The OmniPod System features only two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provide for virtually pain-free automated cannula insertion, communicate wirelessly and integrate a blood glucose meter. In January 2010, the Company entered into a distribution agreement with Ypsomed Distribution AG (Ypsomed), to become distributor of the OmniPod System in 11 countries. In June 2011, the Company acquired Neighborhood Diabetes, Inc.

http://www.google.com/finance?q=PODD